AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...

Two years after AbbVie’s loss of market exclusivity for Humira, those “How it Started and How it’s Going” memes are looking ...

AbbVie Q4 earnings beat estimates, driven by strong sales of Skyrizi and Rinvoq, with an updated 2027 combined revenue ...

Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth in 2025.

ABBV stock, with 24% returns since the beginning of 2024, has marginally underperformed the S&P 500 index, up 27%. An ...

Artificial intelligence (AI) is transforming various industries as a major investing theme in 2025. The technology's ability ...

Novartis issued stronger guidance than Wall Street expected. Elsewhere, Eisai and Biogen’s Alzheimer’s drug will get a closer ...

Rinvoq to $31B amid Humira decline. Skyrizi hit $11.7B and Rinvoq $5.97B in 2024, while Humira fell to $9B from $14.4B in ...

He emphasized the consistent outperformance of the ex-Humira platform, which grew over 18% annually and accelerated to 22% growth in Q4. The company projects mid-single-digit revenue growth in 2025, ...

Read about AbbVie, Novartis, ResMed and more in the latest Market Talks covering the Health Care sector.

Skyrizi and Rinvoq are expected to generate nearly $24 billion in combined sales in 2025, reflecting a $6 billion increase year-over-year. AbbVie raised its 2027 combined sales guidance for these ...